On May 29, ImmunityBio fell 5.12% in regular trading, trading at $7.285/share, with trading volume of $29.54 million. The stock had rebounded 5.66% on May 26 following consecutive declines of 7.89% and 5.23% on May 21 and May 22 respectively, but failed to sustain upward momentum.

The renewed decline reflects continued profit-taking pressure after a cluster of positive catalysts were fully priced in. Key catalysts previously released include positive AUA clinical efficacy data for its bladder cancer program, an ISPOR health economics analysis demonstrating ANKTIVA combined with BCG offers superior cost-effectiveness versus TAR-200, and a competitive landscape benefit from rival enGene's key clinical data failure. Despite this favorable fundamental backdrop, the concentrated realization of multiple catalysts has triggered sustained selling pressure that the May 26 technical bounce was unable to absorb.

ImmunityBio is a clinical-stage biotechnology company focused on developing immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, and natural killer cell therapies targeting bladder, pancreatic, and lung cancers.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)